Antibody Malnutrition-Inflammation Complex Syndrome In Dialysis Patients
all-antibody

Malnutrition-Inflammation Complex Syndrome In Dialysis Patients

Robust affiliation between malnutrition, irritation, and atherosclerosis in power renal failure.

Background

Atheroscleroticcardiovascular illness and malnutrition are widely known as main causes of the elevated morbidity and mortality noticed in uremic sufferers. C-reactive protein (CRP), an acute-phase protein, is a predictor of cardiovascular mortality in nonrenal affected person populations. In power renal failure (CRF), the prevalence of an acute-phase response has been related to an elevated mortality.

METHODS

100 and 9 predialysis sufferers (age 52 +/- 1 years) with terminal CRF (glomerular filtration charge 7 +/- 1 ml/min) have been studied. Through the use of noninvasive B-mode ultrasonography, the cross-sectional carotid intima-media space was calculated, and the presence or absence of carotid plaques was decided.

Dietary standing was assessed by subjective world evaluation (SGA), dual-energy x-ray absorptiometry (DXA), serum albumin, serum creatinine, serum urea, and 24-hour urine urea excretion. The presence of an inflammatory response was assessed by CRP, fibrinogen (N = 46), and tumor necrosis factor-alpha (TNF-alpha; N = 87). Lipid parameters, together with Lp(a) and apo(a)-isoforms, in addition to markers of oxidative stress (autoantibodies in opposition to oxidized low-density lipoprotein and vitamin E), have been additionally decided.

RESULTS

In contrast with wholesome controls, CRF sufferers had an elevated imply carotid intima-media space (18.3 +/- 0.6 vs. 13.2 +/- 0.7 mm2, P < 0.0001) and a better prevalence of carotid plaques (72 vs. 32%, P = 0.001). The prevalence of malnutrition (SGA 2 to 4) was 44%, and 32% of all sufferers had an acute-phase response (CRP>> or = 10 mg/liter).

 

Malnourished sufferers had larger CRP ranges (23 +/- Three vs. 13 +/- 2 mg/liter, P < 0.01), elevated calculated intima-media space (20.2 +/- 0.eight vs. 16.9 +/- 0.7 mm2, P < 0.01) and a better prevalence of carotid plaques (90 vs. 60%, P < 0.0001) in contrast with well-nourished sufferers.

 

Throughout stepwise multivariate evaluation adjusting for age and gender, vitamin E (P < 0.05) and CRP (P < 0.05) remained related to an elevated intima-media space. The presence of carotid plaques was considerably related to age (P < 0.001), log oxidized low-density lipoprotein (oxLDL; P < 0.01), and small apo(a) isoform dimension (P < 0.05) in a multivariate logistic regression mannequin.

all-antibody
all-antibody

CONCLUSIONS

These outcomes point out that the quickly growing atherosclerosis in superior CRF seems to be attributable to a synergism of various mechanisms, similar to malnutrition, irritation, oxidative stress, and genetic parts. Aside from basic danger components, low vitamin E ranges and elevated CRP ranges are related to an elevated intima-media space, whereas small molecular weight apo(a) isoforms and elevated ranges of oxLDL are related to the presence of carotid plaques.

GPR61 Antibody
DF2755 200ul
EUR 420

GPR61 Antibody
DF2810 200ul
EUR 420

GPR61 Polyclonal Antibody
ABP58695-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of GPR61 from Human, Mouse. This GPR61 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human GPR61 protein at amino acid sequence of 190-270

GPR61 Polyclonal Antibody
ABP58695-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of GPR61 from Human, Mouse. This GPR61 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human GPR61 protein at amino acid sequence of 190-270

GPR61 Polyclonal Antibody
ABP58695-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of GPR61 from Human, Mouse. This GPR61 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human GPR61 protein at amino acid sequence of 190-270

GPR61 Conjugated Antibody
C44933 100ul
EUR 476.4

GPR61 Polyclonal Antibody
ES11477-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against GPR61 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

GPR61 Polyclonal Antibody
ES11477-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against GPR61 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

GPR61 siRNA
20-abx918539
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

GPR61 siRNA
20-abx918540
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

GPR61 Recombinant Protein (Human)
RP013882 100 ug Ask for price

GPR61 Recombinant Protein (Rat)
RP203447 100 ug Ask for price

GPR61 Recombinant Protein (Mouse)
RP139673 100 ug Ask for price

GPR61 cloning plasmid
CSB-CL866330HU-10ug 10ug
EUR 279.6
Description: A cloning plasmid for the GPR61 gene.

GPR61 Blocking Peptide
DF2755-BP 1mg
EUR 234

GPR61 Blocking Peptide
DF2810-BP 1mg
EUR 234

Polyclonal GPR61 Antibody (C-Terminus)
APR16588G 0.05mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (C-Terminus). This antibody is tested and proven to work in the following applications:

Polyclonal GPR61 Antibody (C-Terminus)
APR16589G 0.05mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (C-Terminus). This antibody is tested and proven to work in the following applications:

Polyclonal GPR61 Antibody (Cytoplasmic Domain)
APR16590G 0.05mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (Cytoplasmic Domain). This antibody is tested and proven to work in the following applications:

Polyclonal GPR61 Antibody (Extracellular Domain)
APR16591G 0.05mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (Extracellular Domain). This antibody is tested and proven to work in the following applications:

Polyclonal GPR61 Antibody (N-Terminus)
APR16592G 0.05mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (N-Terminus). This antibody is tested and proven to work in the following applications:

Polyclonal Goat anti-GST α-form
GST-ANTI-1 50 uL
EUR 336

Polyclonal Goat anti-GST μ-form
GST-ANTI-2 50 uL
EUR 336

Polyclonal Goat anti-GST p-form
GST-ANTI-3 50 uL
EUR 336

Human GPR61 shRNA Plasmid
20-abx963213
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Mouse GPR61 shRNA Plasmid
20-abx981729
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Probable G-Protein Coupled Receptor 61 (GPR61) Antibody
20-abx147479
  • EUR 510.00
  • EUR 410.40
  • 100 ug
  • 50 ug

Probable G-Protein Coupled Receptor 61 (GPR61) Antibody
abx147480-100ug 100 ug
EUR 526.8

Gpr61 ORF Vector (Rat) (pORF)
ORF067817 1.0 ug DNA
EUR 607.2

GPR61 ORF Vector (Human) (pORF)
ORF004628 1.0 ug DNA
EUR 114

Gpr61 ORF Vector (Mouse) (pORF)
ORF046559 1.0 ug DNA
EUR 607.2

GPR61 Protein Vector (Human) (pPB-C-His)
PV018509 500 ng
EUR 394.8

GPR61 Protein Vector (Human) (pPB-N-His)
PV018510 500 ng
EUR 394.8

GPR61 Protein Vector (Human) (pPM-C-HA)
PV018511 500 ng
EUR 394.8

GPR61 Protein Vector (Human) (pPM-C-His)
PV018512 500 ng
EUR 394.8

GPR61 Protein Vector (Mouse) (pPB-C-His)
PV186234 500 ng
EUR 723.6

GPR61 Protein Vector (Mouse) (pPB-N-His)
PV186235 500 ng
EUR 723.6

GPR61 Protein Vector (Mouse) (pPM-C-HA)
PV186236 500 ng
EUR 723.6

GPR61 Protein Vector (Mouse) (pPM-C-His)
PV186237 500 ng
EUR 723.6

GPR61 Protein Vector (Rat) (pPB-C-His)
PV271266 500 ng
EUR 723.6

GPR61 Protein Vector (Rat) (pPB-N-His)
PV271267 500 ng
EUR 723.6

GPR61 Protein Vector (Rat) (pPM-C-HA)
PV271268 500 ng
EUR 723.6

GPR61 Protein Vector (Rat) (pPM-C-His)
PV271269 500 ng
EUR 723.6

GPR61 sgRNA CRISPR Lentivector set (Human)
K0892201 3 x 1.0 ug
EUR 406.8

Gpr61 sgRNA CRISPR Lentivector set (Rat)
K6526201 3 x 1.0 ug
EUR 406.8

Gpr61 sgRNA CRISPR Lentivector set (Mouse)
K3882801 3 x 1.0 ug
EUR 406.8

GPR61 sgRNA CRISPR Lentivector (Human) (Target 1)
K0892202 1.0 ug DNA
EUR 184.8

GPR61 sgRNA CRISPR Lentivector (Human) (Target 2)
K0892203 1.0 ug DNA
EUR 184.8

GPR61 sgRNA CRISPR Lentivector (Human) (Target 3)
K0892204 1.0 ug DNA
EUR 184.8

Gpr61 sgRNA CRISPR Lentivector (Rat) (Target 1)
K6526202 1.0 ug DNA
EUR 184.8

Gpr61 sgRNA CRISPR Lentivector (Rat) (Target 2)
K6526203 1.0 ug DNA
EUR 184.8

Gpr61 sgRNA CRISPR Lentivector (Rat) (Target 3)
K6526204 1.0 ug DNA
EUR 184.8

Gpr61 sgRNA CRISPR Lentivector (Mouse) (Target 1)
K3882802 1.0 ug DNA
EUR 184.8

Gpr61 sgRNA CRISPR Lentivector (Mouse) (Target 2)
K3882803 1.0 ug DNA
EUR 184.8

Gpr61 sgRNA CRISPR Lentivector (Mouse) (Target 3)
K3882804 1.0 ug DNA
EUR 184.8

GPR61 3'UTR Luciferase Stable Cell Line
TU009173 1.0 ml
EUR 1825.2

Gpr61 3'UTR GFP Stable Cell Line
TU255385 1.0 ml Ask for price

GPR61 3'UTR GFP Stable Cell Line
TU059173 1.0 ml
EUR 1825.2

Gpr61 3'UTR Luciferase Stable Cell Line
TU205385 1.0 ml Ask for price

Gpr61 3'UTR Luciferase Stable Cell Line
TU109034 1.0 ml Ask for price

Gpr61 3'UTR GFP Stable Cell Line
TU159034 1.0 ml Ask for price

Mouse Probable G- protein coupled receptor 61, Gpr61 ELISA KIT
ELI-31707m 96 Tests
EUR 1038

Human Probable G- protein coupled receptor 61, GPR61 ELISA KIT
ELI-32663h 96 Tests
EUR 988.8

GPR61 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
K0892205 3 x 1.0 ug
EUR 451.2

Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)
K6526205 3 x 1.0 ug
EUR 451.2

Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
K3882805 3 x 1.0 ug
EUR 451.2

GPR61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
K0892206 1.0 ug DNA
EUR 200.4

GPR61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
K0892207 1.0 ug DNA
EUR 200.4

GPR61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)
K0892208 1.0 ug DNA
EUR 200.4

Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)
K6526206 1.0 ug DNA
EUR 200.4

Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)
K6526207 1.0 ug DNA
EUR 200.4

Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)
K6526208 1.0 ug DNA
EUR 200.4

Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)
K3882806 1.0 ug DNA
EUR 200.4

Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)
K3882807 1.0 ug DNA
EUR 200.4

Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)
K3882808 1.0 ug DNA
EUR 200.4

Anti-PML Protein Antibody
PB10084 100ug/vial
EUR 400.8

Anti-PML Protein Antibody
PB10085 100ug/vial
EUR 400.8

Anti-Protein Z antibody
STJ98340 100 µl
EUR 280.8
Description: Mouse monoclonal to Protein Z.

Anti-Protein C antibody
STJ96586 200 µl
EUR 236.4
Description: Rabbit polyclonal to Protein C.

Anti-Random protein antibody
STJ140013 150 µg
EUR 262.8
Description: Goat polyclonal antibody to Random recombinant protein fragment. This Random recombinant protein fragment does not have any homology to known protein sequence. This antibody can be used in biochemical and cell biology experiments as a negative control.

Anti-ALK Protein antibody
STJ16100308 1 mL
EUR 1594.8

Anti-CutA protein antibody
STJ73349 100 µg
EUR 430.8

Anti-Protein Vestigial Antibody
STJ503515 100 µg
EUR 571.2

 

Malnutrition-inflammation complicated syndrome in dialysis sufferers: causes and penalties.

BACKGROUND

Atherosclerotic heart problems and malnutrition are widely known as main causes of the elevated morbidity and mortality noticed in uremic sufferers. C-reactive protein (CRP), an acute-phase protein, is a predictor of cardiovascular mortality in nonrenal affected person populations. In power renal failure (CRF), the prevalence of an acute-phase response has been related to an elevated mortality.

 

METHODS

 

100 and 9 predialysis sufferers (age 52 +/- 1 years) with terminal CRF (glomerular filtration charge 7 +/- 1 ml/min) have been studied. Through the use of noninvasive B-mode ultrasonography, the cross-sectional carotid intima-media space was calculated, and the presence or absence of carotid plaques was decided.

 

Dietary standing was assessed by subjective world evaluation (SGA), dual-energy x-ray absorptiometry (DXA), serum albumin, serum creatinine, serum urea, and 24-hour urine urea excretion.

The presence of an inflammatory response was assessed by CRP, fibrinogen (N = 46), and tumor necrosis factor-alpha (TNF-alpha; N = 87). Lipid parameters, together with Lp(a) and apo(a)-isoforms, in addition to markers of oxidative stress (autoantibodies in opposition to oxidized low-density lipoprotein and vitamin E), have been additionally decided.

RESULTS

In contrast with wholesome controls, CRF sufferers had an elevated imply carotid intima-media space (18.3 +/- 0.6 vs. 13.2 +/- 0.7 mm2, P < 0.0001) and a better prevalence of carotid plaques (72 vs. 32%, P = 0.001). The prevalence of malnutrition (SGA 2 to 4) was 44%, and 32% of all sufferers had an acute-phase response (CRP>> or = 10 mg/liter).

 

Malnourished sufferers had larger CRP ranges (23 +/- Three vs. 13 +/- 2 mg/liter, P < 0.01), elevated calculated intima-media space (20.2 +/- 0.eight vs. 16.9 +/- 0.7 mm2, P < 0.01) and a better prevalence of carotid plaques (90 vs. 60%, P < 0.0001) in contrast with well-nourished sufferers.

Throughout stepwise multivariate evaluation adjusting for age and gender, vitamin E (P < 0.05) and CRP (P < 0.05) remained related to an elevated intima-media space. The presence of carotid plaques was considerably related to age (P < 0.001), log oxidized low-density lipoprotein (oxLDL; P < 0.01), and small apo(a) isoform dimension (P < 0.05) in a multivariate logistic regression mannequin.

 

CONCLUSIONS

These outcomes point out that the quickly growing atherosclerosis in superior CRF seems to be attributable to a synergism of various mechanisms, similar to malnutrition, irritation, oxidative stress, and genetic parts. Aside from basic danger components, low vitamin E ranges and elevated CRP ranges are related to an elevated intima-media space, whereas small molecular weight apo(a) isoforms and elevated ranges of oxLDL are related to the presence of carotid plaques.

  • Protein-energy malnutrition (PEM) and irritation are widespread and often concurrent in upkeep dialysis sufferers. Many components that seem to result in these 2 situations overlap, as do evaluation instruments and such standards for detecting them as hypoalbuminemia.
  • Each these situations are associated to poor dialysis end result. Low urge for food and a hypercatabolic state are amongst widespread options. PEM in dialysis sufferers has been advised to be secondary to irritation; nonetheless, the proof isn’t conclusive, and an equicausal standing and even reverse causal route is feasible.
  • Therefore, malnutrition-inflammation complicated syndrome (MICS) is an applicable time period. Attainable causes of MICS embody comorbid diseases, oxidative and carbonyl stress, nutrient loss by means of dialysis, anorexia and low nutrient consumption, uremic toxins, decreased clearance of inflammatory cytokines, quantity overload, and dialysis-related components.
  • MICS is believed to be the primary reason behind erythropoietin hyporesponsiveness, excessive charge of cardiovascular atherosclerotic illness, decreased high quality of life, and elevated mortality and hospitalization in dialysis sufferers.
  • As a result of MICS results in a low physique mass index, hypocholesterolemia, hypocreatininemia, and hypohomocysteinemia, a “reverse epidemiology” of cardiovascular dangers can happen in dialysis sufferers.
  • Due to this fact, weight problems, hypercholesterolemia, and elevated blood ranges of creatinine and homocysteine look like protecting and paradoxically related to a greater end result.
  • There isn’t a consensus about tips on how to decide the diploma of severity of MICS or tips on how to handle it. A number of diagnostic instruments and therapy modalities are mentioned. Profitable administration of MICS might ameliorate the cardiovascular epidemic and poor end result in dialysis sufferers.
  • Scientific trials specializing in MICS and its doable causes and penalties are urgently required to enhance poor medical end result in dialysis sufferers.

Recombinant EBV EBNA1 Mosaic Protein, His, E.coli-100ug
QP11732-100ug 100ug
EUR 261.6

Recombinant EBV EBNA1 Mosaic Protein, His, E.coli-1mg
QP11732-1mg 1mg
EUR 1273.2

Recombinant EBV EBNA1 Mosaic Protein, His, E.coli-500ug
QP11732-500ug 500ug
EUR 795.6

EBNA1 protein
30-1925 500 ug
EUR 678
Description: Purified Recombinant EBNA1 protein

Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [His]
VAng-2528Lsx-100g 100 µg
EUR 555.6
Description: EBV EBNA1 Mosaic protein, His tag at C-terminus, recombinant protein from E. coli.

Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [His]
VAng-2528Lsx-1mg 1 mg
EUR 3360
Description: EBV EBNA1 Mosaic protein, His tag at C-terminus, recombinant protein from E. coli.

Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [His]
VAng-2528Lsx-500g 500 µg
EUR 2040
Description: EBV EBNA1 Mosaic protein, His tag at C-terminus, recombinant protein from E. coli.

Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [GST]
VAng-Lsx0111-100g 100 µg
EUR 759.6
Description: EBV EBNA1 Mosaic protein [GST], recombinant protein from E. coli.

Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [GST]
VAng-Lsx0111-500g 500 µg
EUR 2419.2
Description: EBV EBNA1 Mosaic protein [GST], recombinant protein from E. coli.

pCXWB- EBNA1
PVT10196 2 ug
EUR 361.2

Recombinant (E.Coli, GST tag) Epstein-Barr Virus (EBV/HHV-4) Mosaic EBNA1
RP-347 100 ug
EUR 343.2

EBNA1 protein (His tag)
80-1340 100 ug
EUR 289.2
Description: Purified recombinant EBNA1 protein (His tag)

Recombinant EBNA1 Protein [GST]
VAng-Lsx0122-100g 100 µg
EUR 818.4
Description: EBNA1 (EBV) (P03211) partial recombinant protein with GST tag expressed in E. coli.

EBV protein
30-1275 1 mg
EUR 4177.2
Description: Purified recombinant EBV protein

EBV protein
30-1276 1 mg
EUR 4177.2
Description: Purified recombinant EBV protein

EBV Protein
abx069822-1ml 1 ml
EUR 828

EBV Protein
abx069824-1mg 1 mg
EUR 1762.8

EBV Protein
abx069825-1ml 1 ml
EUR 376.8

EBV Protein
abx069828-1mg 1 mg
EUR 2180.4

EBV Protein
abx069829-1mg 1 mg
EUR 2131.2

EBNA1 Binding Protein 2 Protein
20-abx260778
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

pCXWB- EBNA1 Plasmid
PVT7175 2 ug
EUR 319.2

EBV EA protein
30R-AE005 100 ug
EUR 392.4
Description: Purified recombinant EBV EA protein

EBV p18 protein
30R-AE007 500 ug
EUR 967.2
Description: Purified recombinant EBV p18 protein

EBV p23 protein
30R-AE008 100 ug
EUR 392.4
Description: Purified recombinant EBV p23 protein

EBV EA protein
30-1280 1 mg
EUR 4177.2
Description: Purified recombinant EBV EA protein

EBV VCA protein
30-1811 1 ml
EUR 457.2
Description: Purified native EBV VCA gp125 protein

EBV EA protein
30-1920 1 ml
EUR 496.8
Description: Viral lysate containing a high concentration of EBV antigens, including VCA, EBNA, EA-D and EA-R

EBV EBNA protein
30-AE46 200 ug
EUR 900
Description: Purified recombinant EBV EBNA protein

EBV EA protein
30-AE50 200 ug
EUR 975.6
Description: Purified recombinant EBV EA protein

Recombinant EBV Protein
VAng-Lsx0108-inquire inquire Ask for price
Description: EBV, recombinant protein from human cells.

EBNA1 (GFP-Puro) Lentivirus
LVP1134-GP 1x107 IFU/ml x 200ul
EUR 418.8
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA1 gene under EF1a promoter, containing GFP-Puromycin dual marker.

EBNA1 (RFP-Bsd) Lentivirus
LVP1134-RB 1x107 IFU/ml x 200ul
EUR 418.8
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA1 gene under EF1a promoter, containing RFP-Blasticidin dual marker.

EBNA1 Binding Protein 2 (EBNA1BP2) Antibody
20-abx123650
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

EBNA1 Binding Protein 2 (EBNA1BP2) Antibody
abx026949-400ul 400 ul
EUR 627.6

EBNA1 Binding Protein 2 (EBNA1BP2) Antibody
abx026949-80l 80 µl
EUR 343.2

EBV [His]
DAG1578 100 µg
EUR 972

EBV [GST]
DAG1580 100 µg
EUR 774

EBV [GST]
DAG1581 100 µg
EUR 972

EBV [His]
DAG1584 100 µg
EUR 972

EBV antibody
10-E40C 200 ug
EUR 274.8
Description: Mouse monoclonal EBV antibody

EBV antibody
10-E40D 200 ug
EUR 163.2
Description: Mouse monoclonal EBV antibody

EBV antibody
10-E40E 200 ug
EUR 254.4
Description: Mouse monoclonal EBV antibody

EBV Virus
G229 10 ml
EUR 882

EBV P18 Mosaic protein
DAG1582 100 µg
EUR 774

EBV VCA p23 Protein
abx069823-1mg 1 mg
EUR 1796.4

Recombinant EBV Protein [His]
VAng-Lsx0112-inquire inquire Ask for price
Description: EBV [His], recombinant protein from E. coli.

Recombinant EBV P125 Protein
VAng-Lsx0119-1mL 1 mL
EUR 465.6
Description: EBV P125 Protein, recombinant protein from E. coli.

Recombinant EBV P125 Protein
VAng-Lsx0119-25mL 25 mL
EUR 7318.8
Description: EBV P125 Protein, recombinant protein from E. coli.

Epstein-Barr Virus (HHV-4) EBNA1 Protein
20-abx260340
  • EUR 1345.20
  • EUR 560.40
  • EUR 2364.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Recombinant EBNA1 Protein [His] (1.185 mg/mL)
VAng-0610Lsx-inquire inquire Ask for price
Description: Epstein-Barr Virus (EBV) Nuclear Antigen-1 (EBNA-1), recombinant protein from E. coli. MW 63 kDa, 1.185 mg/mL.

Recombinant EBNA1 Protein [His] (1.25 mg/mL)
VAng-0611Lsx-inquire inquire Ask for price
Description: Epstein-Barr Virus (EBV) Nuclear Antigen-1 (EBNA-1), recombinant protein from E. coli. MW 63 kDa, 1.25 mg/mL.

EBNA1BP2 EBNA1 Binding Protein 2 Human Recombinant Protein
PROTQ99848 Regular: 20ug
EUR 380.4
Description: Recombinant Human EBNA1BP2 produced in E. coli is a single polypeptide chain containing 329 amino acids (1-306) and having a molecular mass of 37.2kDa.;EBNA1BP2 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

EBV HHV-4 p23 Protein
abx060518-1mg 1 mg
EUR 2264.4

EBV p54 (EA-D) Protein
abx061433-1mg 1 mg
EUR 1813.2

EBV p18 protein (His tag)
80-1355S 100 ug
EUR 289.2
Description: Purified recombinant EBV p18 protein (His tag)

EBV p54 protein (His tag)
80-1361 1 mg
EUR 1299.6
Description: Purified recombinant EBV p54 protein (His tag)

EBV p138 protein (His tag)
80-1362 1 mg
EUR 1299.6
Description: Purified recombinant EBV p138 protein (His tag)

Recombinant EBV P138 Protein [His]
VAng-0612Lsx-inquire inquire Ask for price
Description: EBV p138 Early Antigen D (EA-D) Protein, recombinant protein from E. coli. 1.00 mg/mL.

Recombinant EBV P54 Protein [His]
VAng-0613Lsx-inquire inquire Ask for price
Description: EBV p54 Early Antigen D (EA-D) Protein, recombinant protein from E. coli. 1.068 mg/mL.

Recombinant EBV P18 Protein [His]
VAng-0614Lsx-inquire inquire Ask for price
Description: EBV Viral Capsid Antigen (VCA) p18, recombinant protein from E. coli. 2.14 mg/mL.

Recombinant EBV p23 Protein [GST]
VAng-0617Lsx-inquire inquire Ask for price
Description: EBV p23, recombinant protein from E. coli. 1.00 mg/mL.

Recombinant EBV P18 Mosaic Protein
VAng-Lsx0115-inquire inquire Ask for price
Description: EBV P18 Mosaic protein, recombinant protein from E. coli.

Recombinant EBV P23 Protein [His]
VAng-Lsx0117-inquire inquire Ask for price
Description: Recombinant EBV p23 protein was expressed in E. coli and purified by proprietary chromatographic technique, 17.7kDa.

Recombinant EBV BFRF3 Protein [GST]
VAng-Lsx0120-inquire inquire Ask for price
Description: BFRF3 (EBV) (P14348) partial recombinant protein with GST tag expressed in E. coli.

Recombinant EBV BMRF1 Protein [GST]
VAng-Lsx0121-inquire inquire Ask for price
Description: BMRF1 (EBV) (P03191) partial recombinant protein with GST tag expressed in E. coli.

Inactivated EBV gp125 VCA Protein
VAng-Lsx04574-1mL 1 mL
EUR 423.6
Description: Epstein-Barr Virus (Strain P3HR1) gp125 VCA, inactivated antigen.

Inactivated EBV gp125 VCA Protein
VAng-Lsx04574-25mL 25 mL
EUR 7318.8
Description: Epstein-Barr Virus (Strain P3HR1) gp125 VCA, inactivated antigen.

EBV Glycoprotein 125
DAG3085 25 ml
EUR 1966.8

Recombinant EBV p18
DAGA-3074 100ug
EUR 1279.2

EBV BMRF1 [GST]
DAG1849 500 ug
EUR 3034.8

EBV antibody (VCA)
10-E40B 200 ug
EUR 274.8
Description: Mouse monoclonal EBV antibody (VCA)

EBV LMP2A Antibody
abx021712-025mg 0.25 mg
EUR 1212

Inactivated EBV Antigen
VAng-Lsx0109-1mL 1 mL
EUR 1632
Description: EBV, natural antigen.

Human EBNA1 Binding Protein 2 (EBNA1BP2) ELISA Kit
abx384822-96tests 96 tests
EUR 1093.2

Epstein-Barr Virus (HHV-4) Mosaic EBNA1 Protein
20-abx260113
  • EUR 1062.00
  • EUR 410.40
  • EUR 1646.40
  • 0.5 mg
  • 100 ug
  • 1 mg

Mouse EBNA1 Binding Protein 2 (EBNA1BP2) ELISA Kit
abx389130-96tests 96 tests
EUR 1093.2